Topic Listing for Celldex Therapeutics, Inc.

Ability Obtain Substantial Additional Funding Acceleration Options
Accordance Requirements 409a Including Notices Issued Irs Thereunder Accounting Changes
Accounting Changes Error Corrections Accounting Impairment Long-lived Assets
Accounting Patent Costs Accounting Revenue Arrangements Multiple Deliverables
Accounting Uncertainty Income Taxes Accounts Receivable
Accounts Receivable Significant Customers Accrued Clinical Research Contract Manufacturing Costs
Accrued Expenses Acquired In-process Research Development
Acquisitions Acquisitions Lorantis Limited Alteris Therapeutics Inc
Act Act Results
Activate Results Addition Avant Retains Some Participation Worldwide Net Royalty
Additional Agreements Additional Covenants
Additional Information Merger Find Additional Information Transaction Find
Additional Results Adjustments Conversion Price
Administration Objectives Executive Compensation Program Administrator
Adprotech Adprotech Ltd
Aggregate Contractual Obligations Aggregated Option Exercises Last End Values
Agreement Agreement Contract Commitment Relating Capital Expenditures Involving Future
Agreement Deliver Prf Written Evidence Such Instruction Applicable Agreement Plan Merger
Agreements Contracts Commitments Except Described 218 Celldex Disclosure Alf Lindberg Phd
Allowance Disbursement Request Alteris Therapeutics Inc
Alternate Dispute Resolution Amended Restated Employment Agreement
Amendment Purchase Agreement Amendments Waivers
American General Life Insurance Amgen
Amgen Inc Amortization Intangible Assets
Amount Amount Not Deductible Pursuant 280g 162 Code Comparable
Amounts Received Pursuant Sublicenses Granted Avant After Human Animal Health Food Safety Vaccine Programs
Annual Bonus Annual Meeting Stockholders 2009
Annual Report Anthony Marucci
Anthracis Appendix
Applications Patents Avant Collaboration Inventions Expenses Such Preparation Appointment Certain Officers
Approval Application Arbitration
As-built Documents Assumed Obligations
Assumption Notice Attend Meeting
Audit Committee Audit Fees
Audit-related Fees Audits
Authority Authorization
Authorized Capital Stock Automatic Conversion
Avant Agrees Fund Research Program Following Rates Avant Celldex Pro Forma Condensed Combined Financial Statements
Avant Entered Agreement Whereby Affiliate Paul Royalty Avant Entered Agreement Whereby Affiliate Prf Purchased
Avant Had Federal Net Operating Loss Tax Avant Immunotherapeutics Inc
Avant Immunotherapeutics Inc 119 Avenue Needham Massachusetts 02494 Avant Leases Approximately 12400 Square Feet Laboratory Office
Avant Material Adverse Effect Celldex Shall Received Certificate Avant Non-solicitation
Avant Principal Stockholders Avant Reports 2007 Financial Results
Avant Reports Financial Results Conference Call Wednesday 900 Avants Expense Not Often Once Each Avant Sole
Avants Right Select Such Antigen Licensed Product Set Avenue Needham 02194-2725 Usa 781-433-0771 Fax 781-433-0262 Wwwavantimmunecom
Avenue Needham 02494-2725 Usa 781-433-0771 Fax 781-433-0262 Wwwavantimmunecom Avenue Needham 02494-2725 Usa 781-433-0771 Fax 781-433-0262 Wwwcelldextherapeuticscom
Avenue Needham Massachusetts 02494 Avenue Needham Massachusetts 02494 Address Principal Executive Offices
Avenue Needham Massachusetts 02494-2725 Avery Catlin
Award Award Agreement
Background Patent Rights Bacterial Vaccines
Base Building Plans Base Building Work
Base Building Work Commencement Date Base Salary
Basis Presentation Basis Presentation Business Overview
Because Certain Components Exchange Ratio Fluctuate Prior Closing Been Sought Hereunder Such Indemnified Party Unless Settlement
Beneficial Owner Beneficial Ownership Reporting Compliance
Benefits Benefits Payable
Bid Process Billing Invoice Amount Net Sales Shall Not Include
Binding Effect Biodefense Vaccine Programs
Biodefense Vaccines Biolipox Formerly Inflazyme Pharmaceuticals Ltd Adprotech
Biosyn Corporation Board Directors
Board Directors Committees Board Directors Management Avant
Board Directors Recommends Stockholders Vote Approval Amendment 2008 Board Directors Recommends Stockholders Vote Election Director Nominees
Board Directors Recommends Stockholders Vote Ratification Indepdent Registered Board Directors Stockholders Avant Immunotherapeutics Inc
Books Records Brokers Fees
Budget Building
Building System Business Combinations
Business Requires Hazardous Materials Increases Exposure Dangerous Costly C-2
C-3 Calculation Estimated Consideration Transferred
Calling Annual Meeting Campylobacter
Cancer Vaccine Development Programs Candidate Antigen Means Jrc Reasonably Believes Shows Likely
Cannot Sell Capital Stock Raise Necessary Funds Force Cannot Sell Capital Stock Raise Necessary Funds Forced
Cano Capital Requirements
Capital Stock Captions
Cardiovascular Programs Carefully Review Factors Aware
Cash Equivalents Cash Equivalents Marketable Securities
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Operating Activities Cash Provided Financing Activities
Cash Provided Used Investing Activities Cash Provided Used Operating Activities
Cautionary Statements Cdx-110
Cdx-110 Clinical Programs Summary Cdx-110 Pf-04948568
Cdx-110 Vaccine Cdx-1127
Cdx-1135 Formerly Tp10 Cdx-1189
Cdx-1307 Cdx-1401
Cdx-2401 Cell
Celldex Apc Targeting Technology Celldex Contacts
Celldex Curagen Pro Forma Condensed Combined Financial Statements Celldex Employee Plan Maintained Jurisdiction Outside United States
Celldex Financial Statements Celldex Program Patent Rights
Celldex Stockholders Reduced Ownership Voting Interest After Curagen Celldex Therapeutics Announces Appointment Larry Ellberger Chairman Board
Celldex Therapeutics Announces Cdx-1307 Clinical Data Annual Asco Celldex Therapeutics Inc
Celldex Therapeutics Reports 2009 Financial Results Celldex Workplan
Celldexs Business Materially Harmed Celldex Unable Obtain Enforce Certain Factors Negatively Affect Demand Sales Profitability Rotarix
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certificate Amendment Incorporation Avant Immunotherapeutics Inc Certificate Incorporation 149
Certification Certifications
Cgmp Change Control
Changes Control Registrant Changes Independent Accountants
Changes Internal Control Over Financial Reporting Changes Registrants Certifying Accountant
Charles Schaler Charles Schaller
Chicago 2008 Chip Catlin
Choice Law Choleragarde Etec Vaccine
Choleragarde Vaccine Cholesterol Management Vaccine
Cincinnati Childrens Hospital Medical Center Cch Circulation
Clinical Development Program Update Clinical Research Contract Manufacturing Accruals
Clinical Trial Accruals Closing
Code Code Business Conduct Ethics
Collaboration License Agreement Collaboration Patent Means Discloses Claims Invention
Collaboration Term Collaborative Agreements
Combined Ability Net Operating Loss Carryforwards Celldex Avant Combined Ability Net Operating Loss Carryforwards Subsidiaries Subject
Commercialisation Commitments Build-out Fall River Facility
Commitments Contingencies Commitments Fall River Massachusetts Facility
Commitments Licensors Certain Intellectual Property License Agreements Commitments Needham Massachusetts Facility
Commitments Operating Leases Commitments Overland Missouri Facility
Commitments Philipsburg New Jersey Facility Commitments Renovations Fall River Facility
Commitments Renovations Needham Facility Commitments Renovations Needham Facility Improvements Fall River
Common Access Areas Common Hvac
Common Stock Purchase Agreement Compared
Compared 2002 Compared 2003
Compared 2004 Compared 2005
Compared 2006 Compared 2007
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Discussion Analysis 2007 Avant Prior Merger Compensatory Arrangements Certain Officers
Compensatory Plans Competition
Competitors Field They Develop Technologies Make Ours Obsolete Complement Inhibitor
Complement Inhibitors Completion Acquisition Disposition Assets
Compliance Laws Compliance Permits Restrictions
Comply Sec Requirements Securities Act Exchange Requires Public Compounds
Comprehensive Income Comprehensive Loss
Conditions Applicable Avant Conditions Applicable Prf Closing
Conditions Merger Conference Call Friday 900 Eastern Time
Conference Call Information Conference Call Tuesday 900 Eastern Time
Conference Call Wednesday 900 Eastern Time Confidential Information Publication
Confidentiality Public Announcement Confidentiality Publication
Confidentiality Study Results Publication Conflicts
Consent Independent Registered Public Accounting Firm Consents Approvals
Consents Waivers Consideration Received Prf Date Expected Total Payments Paid
Consolidated Balance Sheet Data Consolidated Financial Statements
Construction Documents Construction Manager
Construed Create Limit Such Partys Liability Respect Indemnification Contact Information
Content Contents
Controls Procedures Convertible Preferred Stock
Convertible Subordinated Debt Convertible Subordinated Notes Due 2011
Corixa Corporation Corporate Authorization
Costs Costs Associated Merger Difficult Estimate Higher Expected Harm
Counterparts Counterparts Effectiveness
Covenants Covered Employee
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies
Curagen Acquisition Financial Details Curagen Contacts
Curagen Corporation Curagen Severance Obligations
Current Report Pursuant Securities Exchange Act 1934 David Sugarman
Decrease Demand Megan Vac Egg Other Future Products Decrease Demand Sales Profitability Megan
Decrease Demand Sales Profitability Megan Vac Egg Adversely Deem Advisable Carry Out Intent Accomplish Purposes Agreement
Deferred Compensation Deferred Rent
Deferred Revenue Deferred Savings Plan
Defined Terms Definitions
Delaware Delay Obtaining Regulatory Approval Adverse Impact Ability Earn
Delivery Remedies Delay Departure Directors Certain Officers Compensatory Arrangements
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Departure Directors Principal Officers Election Appointment Departure Directors Principal Officers Election Appointment Certain
Depend Greatly Intellectual Capabilities Experience Key Executives Scientists Depend Greatly Party Collaborators License Develop Commercialize Some
Description Existing 2008 Plan Description Existing Stock Purchase Plan
Description Transaction Basis Presentation Determination Calculation Net Sales
Develo Pment Strategy Development Strategy
Director Compensation Director Compensation 2006
Director Compensation 2007 Director Independence
Director Nominees Directors
Directors Officers Liability Insurance Life Disclosure Schedules
Diseases Distribution Agreement Identifying Contain Exclusivity Provisions
Dividend Equivalent Right Dollars Means
Drug Master Due Landlords Broker Connection Transactions Described Herein
Duke University Duke University Brain Tumor Cancer Center
Duties Dvc Llc Formerly Dynport Vaccine
Dynport License Dynport Vaccine Llc Dvc
Each Celldex Curagen Subject Business Uncertainties Contractual Restrictions Each Parties Hereby Represents Warrants Covenants Follows
Each Party Owns Otherwise Controls Rights Title Interest Each Product Then Seek Partners Help See Those
Early Termination Date Effect Expiration
Effective Date Egfr
Eitf 03-6-1 Eitf 07-1
Eitf 07-3 Either Such Case Breach Not Been Cured Within
Embargoed Until 1015 Cdt Monday 2008 Employee Benefit Plans
Employee Benefits Employee Stock Benefit Plans
Employee Stock Option Plans Employee Stock Purchase Plan
Employees Scientific Consultants Employment Agreement
Employment Agreements Employment Benefit Matters
Employment Contracts Termination Change-of-control Arrangements Enforcement Rights
Entire Agreement Entitled Vote
Entitled Vote Meeting Entry Material Definitive Agreement
Environmental Matters Equity Awards
Equity Compensation Equity Compensation Plan Information
Estimate Total Costs Estimates
Etec Vaccine Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Excess Rent
Exchange Act Exchange Certificates
Excluded Assets Exclusivity Non-competition
Execution Copy Executive Compensation
Executive Compensation Components Executive Officers
Exhibits Expansion Premises
Expansion Premises Commencement Date Expect Continue Incur Operating Losses Combined Need Raise
Expect Incur Significant Costs Integrating Avant Celldex Single Expect Incur Significant Costs Integrating Celldex Curagen Single
Expense Expenses
Expenses Solicitation Expiration Date
Explanatory Extension Research License Period
Extension Term Extinguishment Debt
Face Delays Difficulties Unanticipated Costs Establishing Sales Distribution Face Risk Product Liability Claims Exceed Insurance Coverage
Fail Retain Key Employees Benefits Merger Diminished Failure Complete Curagen Merger Negatively Impact Stock Price
Failure Comply Applicable Regulatory Requirements Adversely Impact Operations Fair Market Value
Fair Value Disclosures Prior Adopting Sfas 123 Fair Value Financial Instruments
Fair Value Measurements Family Relationships
Federal Income Tax Considerations Stock Purchase Plan Federal State Income Tax Liabilities Expire Various Dates
Fees Expenses Fees Milestone Payments
Fees Milestones Royalties Field
Fin Financial Statement Schedules
Financial Statements Businesses Acquired Financial Statements Exhibits
Food Safety Animal Health Vaccines Food Safety Vaccine Products
Force Majeure Delay Foreign Country Such Other Approvals Not Obtained Avant
Foreign Currency Transactions Foreign Currency Translation
Foreign Sales Form 10-k
Form 10-q Form 10-q 2006 Table Contents
Form 10-q 2007 Table Contents Former Name Changed Since Last Report
Forward-looking Statements Forward-looking Statements Based Managements Beliefs Assumptions Information Currently
Francis Cano Phd Fsp Fas 107-1
Fsp Fas 142-3 Funding Request
Funds Available Further Financial Highlights
Further List Description Risks Uncertainties Found Pfizers Annual General
General Administrative Expense Increased 1322919 237 6894951 2005 General Option Information
General Provisions General Terms
George Elston Glaxo Corixa Corporation
Glaxosmithkline Glaxo Glaxosmithkline Glaxo Paul Royalty Fund Prf
Glaxosmithkline Plc Glaxosmithkline Plc Corixa Corporation
Glaxosmithkline Plc Glaxo Glaxosmithkline Plc Glaxo Paul Royalty Fund Prf
Glaxosmithkline Plc Paul Royalty Fund Glen Gechlik
Glioblastoma Multiforme Global Health
Gmp Contract Gmp Contractor
Golden Parachute Payment Provisions Goodwill
Goodwill Intangible Other Assets Governing Law Jurisdiction
Government Regulation Governmental Authorization
Governmental Regulatory Body Authority Indicated Celldex Subsidiaries Intention Grant Rights
Granted Claim Grants Plan-based Awards
Grants Plan-based Awards 2006 Harry Penner
Headings Captions Health Care Reform Restrictions Reimbursement Limit Returns Potential
Henry Marsh Phd Herbert Conrad
Historical Financial Information Not Indicative Future Results Merged History Losses Uncertainty Future Profitability Make Common Stock
Holder Holdover Request
Hsr Identifiable Intangible Assets
Immediate Release 2005 Immediate Release 2006
Immediate Release 2008 Immediate Release 2009
Immediate Release 2010 Immunogenicity Dvcs New Vaccine 2005 Avant Received Notice
Immunotherapeutics Inc Impairment Long-lived Assets
Important Additional Information Filed Sec Important Information Related Celldexs Financial Results
Improvement Improvement Allowance
Incentive Stock Option Incentive Stock Option Agreement
Income Loss Per Share Continuing Operations Income Taxes
Indemnification Indemnification Insurance
Independent Nature Relationship Independent Registered Public Accounting Firm
Index Index Schedules Exhibits
Indicate Check Registrant Not Required Reports Pursuant Act Indicate Check Whether Registrant Shell Defined Rule 12b-2
Infectious Disease Development Programs Inflammatory Disease Development Programs
Inflazyme Formerly Adprotech Inflazyme Formerly Adprotech Ltd
Inflazyme Pharmaceuticals Ltd Formerly Adprotech Information Regarding Nominees Executive Officers
Infra Initial Research License Period
Insurance Intangible Assets
Integrating Companies Divert Managements Attention Away Operations Integrating Curagens Organization Divert Managements Attention Away Operations
Intellectual Property Intentionally Omitted
Interest Capitalization Interim Disclosures Fair Value Financial Instruments
Interim Financial Statements Internal Control Over Financial Reporting
Internal Control-integrated Framework Interpretation
Introduction Inventions
Investment Income Net Investment Other Income Net
Investment Securities Japan
Jason Kantor Jeremy Stoval
Joint Collaboration Invention Means Created Conceived Jointly Avant Joint Press Release
Joint Research Committee Jonathan Aschoff
Jrc Fails Reach Unanimous Agreement Matter Before Consideration Karen Shoos Lipton
Know-how Confidential Information Know-how Include
Labor Matters Lancet
Landlord Landlord Parties
Landlords Landlords Broker
Landlords Expansion Premises Work Landlords Proposed Lease Notice
Larry Ellberger Latest Gsk Report Sales Rotarix
Lease Lease Shall Amended Delete Name Michael Furlong
Lease Shall Amended Include Following Leases
Legal Opinions Legal Proceedings
Legal Requirements Lender
Level License
License Agreements License Avant Licensed Products
License Technology Other Companies Develop Products Those Influence License Technology Other Companies Develop Products Those Restrict
Licensed Compound Licensed Product
Licensed Product Means Containing Target Antigen Related Influenza Licensed Territory Means Worldwide
Licenses Licenses Research Program
Limitation Deductions Lindberg
Liquidity Capital Resources List Exhibits
List Subsidiaries Litigation
Loan Loan Payable
Lohmann Animal Health International Lahi Long-lived Assets
Long-term Liabilities Long-term Liabilities Deferred Revenue
Lorantis Limited Lose Listing Nasdaq Global Market Stock Price Falls
Loss Per Share Ludwig Institute Cancer Research
Major Collaborators Geographical Information Major Commercial Markets Well Timing Success Worldwide Commercialization
Managements Annual Report Internal Control Over Financial Reporting Managements Report Internal Control Over Financial Reporting
Manufacturing Market Registrants Common Equity Related Stockholder Matters Issuer
Marketed Products Marketing
Material Modification Rights Security Holders Medarex
Medarex Holds Approximately Shares 2008 Mederax Other Stockholders Medarex Inc
Megan Megan Egg
Megan Health Inc Megan Vac
Megan Vac Egg Vaccines Mepfp
Merger Merger Agreement Between Curagen
Merger Agreement Celldex Merger Avant Celldex
Merger Between Avant Celldex Merger Between Avant Celldex Research
Merger Between Celldex Research Merger Between Curagen
Merger Celldex Merger Celldex Research
Milestone Avant Pay Select Later After Obtaining Mitigation
Modification Waiver Nature Business
Nature Business Overview Needham
Needham 2005 Needham 2006
Needham 2008 Needham 2010
Needham Branford 2009 Needham Mass
Needham Mass 2009 Needham Massachusetts 02494-2725
Needham Phillipsburg 2007 Net Loss
Net Loss Per Share Net Operating Loss Carryforwards
New Plan Benefits Nine-month Period 2006 Compared 2005
Nolo Contendere Nominating Corporate Governance Committee
Nominees Election Non-competition
Non-competition Non-solicitation Non-disclosure Confidential Information
Non-employee Director Non-employee Grants
Non-solicitation Employees Nonqualified Deferred Compensation
Nonrefundable License Fee Due Payable Later Fifteen After Not Able Successfully Integrate Newly Acquired Technology Existing
Not Able Successfully Integrate Newly-acquired Technology Existing Modify Not Successful Integrating Companies Able Operate Efficiently After
Not Successful Integrating Curagens Organization Able Operate Efficiently Notes Pro Forma Condensed Combined Financial Statements
Notice Notice Annual Meeting Stockholders
Notice Annual Meeting Stockholders Held 2009 Notice Hereby Given
Notice Required Agreement Given Prepaid Class Certified Mail Notices
Novartis Pharma Now Therefore
Number 0-15006 Number Important Factors Cause Actual Results Differ Materially
Number Shares Issued Outstanding Eligible Vote Record Date Obligations Base Rent Other Noncancelable Operating Leases 2005
Off-balance Sheet Arrangements Officer Anthony Marucci
Operating Expense Operating Expense Exclusions
Operating Leases Option
Option Exercises Stock Vested Option Exercises Stock Vested 2006
Options Granted Last Organization
Organization Basis Presentation Original Lease
Original Premises Other Acquisitions
Other Benefits Other Collateral Respect Clause Above Pursuant Security Agreement
Other Convertible Security Shall Been Authorized Listing Nasdaq Other Events
Other Factors Affect Demand Sales Profitability Other Factors Affect Demand Sales Profitability Megan Vac
Other Factors Affect Demand Sales Profitability Rotarix Current Other Fees
Other Liquidity Matters Other Long-term Liabilities
Other Matters Other Matters Voted Annual Meeting
Outstanding Equity Awards Overview
Owned Operated Occupied Leased Other Those Hazardous Materials Owner
Ownership Ownership Changes Defined Internal Revenue Code Limited Amount
Ownership Intellectual Property Patent Rights Parachute Payments
Pari Passu Park
Part Iv- Cases Preparation Participants Solicitation
Passu Patents
Patents Know-how Warranties Best Knowledge Effective Date Each Patents Licenses Proprietary Rights
Paul Royalty Fund Paul Royalty Funds Capital Partners
Payable Payments Reports
Pension Benefits Percent Owner
Performance Criteria Performance Cycle
Performance Goals Performance Incentive Plan
Performance Share Award Performance Tenant Improvement Work
Performance-based Award Peru-15 Ty800 Ceti-1 Other Preclinical Clinical Testing Ability
Peter Sears Pfizer Animal Health Agreement
Pfizer Avant Enter Licensing Development Agreement Novel Therapeutic Pfizer Celldex Therapeutics Present Update Cdx-110 Pf-04948568 Phase
Pfizer Disclosure Notice Information Contained Release 2008 Assumes Pfizer Inc
Pfizer Inc Working Together Healthier World Pfizer License Development Agreement
Pfizer Oncology Phase Clinical Trial
Place Business Plan
Please Date Sign Mail Proxy Card Envelope Provided Please Sign Date Proxy Card Promptly Return Envelopeprovided
Potential Payments Termination Employment Change Control Precision Targeted Immunotherapy Platform
Preferred Stock Preliminary Allocation Consideration Transferred Net Assets Acquired
Premises Premises Delivery Date
Press Release Press Release Related Slides
Principal Accounting Fees Services Principal Management Stockholders
Principal Stockholders Officers Directors Own Large Percentage Voting Principal Stockholders Sell Shares Common Stock Large Volumes
Pro Forma Adjustments Pro Forma Financial Information
Product Product Development Commercialization
Product Development Licensing Agreements Product Liability
Product Testing Critical Success Products Subject Delay Cancellation Products Cannot Shown Safe Effective Clinical Trials Not
Products Combined Cannot Shown Safe Effective Clinical Trials Products Not Pass Required Tests Safety Effectiveness Able
Products Product Candidates Subject Extensive Regulatory Scrutiny Program Developments
Program Ownership Program Patent Rights
Programs Preclinical Clinical Studies Scope Collaborative Arrangements 2006 Properties
Property Description Property Equipment
Property Equipment Includes Following Property Equipment Leases
Proposal Proposal Ratify Appointment Pricewaterhousecoopers Llp Independent Registered Public
Proprietary Rights Provided
Provision Income Taxes Proxy Materials Including Statement 2009 Annual Meeting 2008
Proxy Solicited Behalf Board Directors Annual Meeting Shareholders Proxy Statement
Public Private Stock Offerings Punch List
Purchase Agreement Purchase Commitments Contract Manufacturing
Purchase Price Purchase Sale
Quantitative Qualitative Disclosures Market Risk Quarterly Report Form 10-q Includes Forward-looking Statements
Quarterly Reports Raise Serum Hdl Cholesterol Levels
Rajesh Parekh Reasonable Best Efforts Further Assurance
Recapitalization Stock Split Recent Accounting Pronouncement
Recent Accounting Pronouncements Recent Highlights
Recent Pronouncements Recently Enacted Pronouncements
Recitals Reclassification
Recommendation Records
Redacted Copy Regarding Cash Balances Capital Requirements Anticipated Royalty Payments
Registrants Telephone Number Including Area Code 781 433-0771 Regulation Disclosure
Regulatory Approval Regulatory Authority
Related Party Transactions Release Contains
Reliance Parties Requires Share Trade Secrets Increases Possibility Rely Contract Manufacturers Cost Delivery Quality Clinical Commercial
Rely Parties Plan Conduct Monitor Clinical Tests Failure Rely Patents Patent Applications Other Intellectual Property Protections
Remediation Material Weakness Remittance Initial Concentration Account
Reparation Plans Specifications Report Audit Committee
Report Avant Compensation Committee Report Compensation Committee
Report Independent Registered Public Accounting Firm Reports Form 8-k
Representation Representations Warranties Avant
Representations Warranties Avant Merger Sub Representations Warranties Celldex
Representations Warranties Prf Requested Period
Required Law Regulation Disclosed Research Collaboration
Research Collaboration Licensing Agreements Research Commercialization Agreement
Research Develop Manufacture Commercialize Licensed Product Provided Royalties Research Development Activities
Research Development Costs Research Development Expense Increased 189469 14063295 2005 Compared
Research Development Expenses Research Development Tax Credit Carryforwards
Research Licensing Agreements Research Rights
Reserved Rights Resignation Executive
Resignation Una Ryan Phd Resolved
Restricted Cash Restricted Stock Award
Restricted Stock Unit Awards Restructuring
Restructuring Activities Restructuring Charges
Results Operations Retained Premises
Retirement Savings Plan Revenue
Revenue Recognition Reverse Stock Split
Revoke Proxy Instructions Rights Discussion
Risk Factors Robert Burns
Rockefeller University Rockefeller University Gates Grand Challenge Award
Ronald Ellis Phd Ronald Newbold
Ronald Newbold Phd Rotarix Royalty Payments
Rotavirus Vaccine Royalty Schedule
Sab 108 Safe Harbor Forward-looking Statements
Safe Harbor Statement Private Securities Litigation Reform Act Salary
Sale Event Sales Unregistered Equity Securities 2008
Salmonella Salmonella Typhi
Schedule 14a Schedule 14a Proxy Statement Pursuant Securities Exchange Act
Science Scott Middleton
Seattle Genetics Inc Collaboration Agreement Securities Exchange
Securities Exchange Act 1934 Security Agreement
Security Instrument Security Ownership Certain Beneficial Owners Management Related Stockholder
See Accompanying Notes Consolidated Financial Statements Segment Information
Segments Select Know-how Means Controlled Effective Date Term Agreement
Select Vaccines Limited Selected Quarterly Financial Data
Selling Stockholders Choose Sell Shares Large Volume Trading Selling Stockholders Choose Sell Shares Large Volumes Trading
Set-off Severability
Severance Arrangements Sfas
Sfas 123r Sfas 141 160
Sfas 154 Sfas 157
Sfas 159 Sfas 162
Sfas 168 Shall Not Considered Failure Make Withdrawal Modification Change
Share Price Been Remain Volatile Share Repurchase Plan
Shareholder Meeting Shareholder Rights Plan
Shares Issued Executive Officers Shigella
Signature Signatures
Significant Accounting Policies Simultaneously Delivery Each Report Avant Pay Select Monies
Six-month Period 2006 Compared 2005 Six-month Period 2007 Compared 2006
Snda Soliciting Proxy
Solvency Some Factors Might Cause Differences Include Following
Space Plan Special Offset Rights
Specific Performance Stock
Stock Appreciation Right Stock Option Plan Description
Stock Performance Graph Stock Plan
Stock-based Compensation Stock-based Compensation Expense
Stockholder Communications Stockholder Proposals 2008 Annual Meeting
Stockholder Proposals 2009 Annual Meeting Stockholder Proposals 2010 Annual Meeting
Stockholder Record Stockholder Rights Plan
Stockholders Equity Stockholders Reduced Ownership Voting Interest After Merger Exercise
Strategy Study
Study Design Sublicensee
Sublicensee Means Party Other Affiliate Licensed Avant Affiliates Submission Matters Vote Security Holders
Subordination Subsequent Event
Subsequent Event-extinguishment Debt Subsequent Events
Subsidiary Substantial Completion Base Building Work
Substantial Completion Objection Substantial Completion Tenant Improvement Work
Successor Successors Assigns
Successors Binding Agreement Summary Compensation Table
Summary Significant Accounting Policies Suppliers Manufacturers Effect Transaction
Survival Surviving Corporation Certificate Incorporation Bylaws
Suspensions Restrictions Individually Aggregate Not Reasonably Expected Celldex Table Contents
Taha Keilani Target Disease Means Specified Appendix
Tax Tax Aspects Code
Tax Fees Technical Collaboration Regulatory Support
Technology Licensing Tenant
Tenant Delay Tenant Expansion Premises Work
Tenant Improvement Allowance Tenant Improvement Work
Tenants Contribution Tenants Representative
Term Term Agreement
Term Agreement Through Expiration Last Relevant Patents Covered Term Termination
Terminated Premises Terminated Premises Surrender Date
Termination Termination Cause
Termination Change Control Termination Disability
Termination Not Sole Remedy Agreement Whether Effected Other Termination Without Cause Good Reason Executive
Thayer Koboroski Therapore
Thomas Davis Thomas Jefferson University
Thomas Jefferson University Tju Three-month Period 2006 Compared 2005
Tibor Keler Tibor Keler Phd
Time Devoted Executive Timothy Cooke Phd
Tom Davis Topotarget Collaboration License Agreement
Total Costs Total Costs Savings
Tp10 Trade Other Accounts Receivable
Transaction Terms Transactions Related Persons
Transfer Costs Transfers Payments Respect Purchased Interest
Travelers Vaccines Treaty Statute Promulgated Governmental Authority Effect Prior Date
Ty800 Typhoid Fever Vaccine Una Ryan
Una Ryan Phd Unable Manage Multiple Late Stage Clinical Trials Variety
Universal Preservation Technologies Inc Universal Preservation Technologies Inc Upt
University Southampton Unregistered Sales Equity Securities
Unrestricted Stock Award Upfront License Fees Avant Pay Select Specified Amounts
Vaccine Adjuvant Vaccine Adjuvant License Collaboration Agreement
Vaccine Technologies Inc Vti Vaccines
Validity Vibrio Cholerae
Virus Research Institute Inc Virus Research Institute Inc Vri
Virus-like Particles Voluntary Conversion
Vote Vote Internet
Vote Mail Vote Person
Vote Required Vote Telephone
Vote Telephone Not Need Return Proxy Card Voting Proxy Holders Shares Registered Directly Name Stockholder
Voting Proxy Holders Shares Registered Name Brokerage Firm Wages Not Received Written Remedial Order Notice Offense
Waiver Waiver Jury Trial
Wall Street Journal Warrants
Warrants Outstanding 2005 Follows Webcast Conference Call
What Boards Recommendations What Broker Non-votes
What Constitutes Quorum What Difference Between Holding Shares Stockholder Record Beneficial
What Other Information Review Before Voting What Purpose Annual Meeting
What Vote Required Approve Each Proposal What Vote Then Change Mind
Whereas Witness Whereof
Workplan Wwwavantimmunecom
Wwwcelldextherapeuticscom 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki